Abstract:Background: Clear cell renal cell carcinoma is the most common and fatal form of kidney cancer, accounting for 80% of new cases. Although it has been reported that GTSE1 is highly expressed in a variety of tumors and associated with malignant progression and poor clinical prognosis, its clinical significance, correlations with immune cell infiltration and biological function in ccRCC are still poorly understood. Methods: The gene expression, clinicopathological features, and clinical significance of GTSE1 were analyzed using multiple databases, including TCGA, GEO, TIMER, and UALCAN Kaplan–Meier survival analysis, gene set enrichment analysis gene ontology enrichment Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed. Tumor-infiltrating immune cells and immunomodulators were extracted and analyzed using TCGA-KIRC profiles. Protein‒protein interactions were built using the STRING website. The protein level of GTSE1 in ccRCC patients was detected by immunohistochemistry using a ccRCC tissue chip. Finally, MTT assays, colony-formation assays, cell flow cytometry analyses, EdU-staining assays, wound-healing assays, and transwell migration and invasion assays were conducted to assess the biological function of GTSE1 in vitro . Results: GTSE1 was overexpressed in ccRCC tissues and cells, and GTSE1 overexpression was associated with adverse clinical-pathological factors and poor clinical prognosis. Meanwhile, the functional enrichment analysis indicated that GTSE1 and its coexpressed genes were mainly related to the cell cycle, DNA replication, and immunoreaction, such as T-cell activation and innate immune response, through multiple signaling pathways, including the P53 signaling pathway and T-cell receptor signaling pathway. Furthermore, we observed a significant relationship between GTSE1 expression and the levels of infiltrating immune cells in ccRCC. Biological functional studies demonstrated that GTSE1 could promote the malignant progression of ccRCC by promoting cell proliferation, cell cycle transition, migration, and invasion capacity and decreasing the sensitivity of ccRCC cells to cisplatin. Conclusion: Our results indicate that GTSE1, serving as a potential oncogene, can promote malignant progression and cisplatin resistance in ccRCC. Additionally, high GTSE1 expression contributes to an increased level of immune cell infiltration and is associated with a worse prognosis, providing a potential target for tumor therapy in ccRCC.

Clinical significance of GTSE 1 expression in colorectal carcinoma

Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer.

Tumor and Serum Gamma-Glutamyl Transpeptidase, New Prognostic and Molecular Interpretation of an Old Biomarker in Gastric Cancer

Up-regulation of GTSE1 lacks a relationship with clinical data in lung cancer.

GSE1 Predicts Poor Survival Outcome in Gastric Cancer Patients by SLC7A5 Enhancement of Tumor Growth and Metastasis.

High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis

Pan-cancer analyses reveal GTSE1 as a biomarker for the immunosuppressive tumor microenvironment.

GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner

GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis

GTSE1 promotes tumor growth and metastasis by attenuating of KLF4 expression in clear cell renal cell carcinoma

GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer

GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma

Overexpression of G2 and S Phase-Expressed-1 Contributes to Cell Proliferation, Migration, and Invasion Via Regulating P53/foxm1/ccnb1 Pathway and Predicts Poor Prognosis in Bladder Cancer.

Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis

Identification of Significant Biomarkers and Pathways Associated with Gastric Carcinogenesis by Whole Genome-Wide Expression Profiling Analysis

G2 and S phase‐expressed‐1 acts as a putative tumor promoter in cervical cancer by enhancing Wnt/β‐catenin signaling via modulation of GSK‐3β

Silencing GTSE-1 Expression Inhibits Proliferation and Invasion of Hepatocellular Carcinoma Cells

The Clinical Significance and Potential Molecular Mechanism of PTTG1 in Esophageal Squamous Cell Carcinoma

High G2 and S-phase Expressed 1 Expression Promotes Acral Melanoma Progression and Correlates with Poor Clinical Prognosis.

Expression and Clinical Significance of ECHS1 in Gastric Cancer.

Identification of GGT5 as a Novel Prognostic Biomarker for Gastric Cancer and its Correlation With Immune Cell Infiltration